News
The FDA has lifted its hold on Elevidys for ambulatory patients, after asking Sarepta to pause the treatment following three ...
Vinay Prasad, a top regulator at the US Food and Drug Administration, has left the agency after a controversy over his ...
Novo Nordisk tapped Maziar Mike Doustdar, its head of international operations, as its new chief executive officer and ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients ...
Brown University took out another private loan, securing a $500 million agreement after the Ivy League school warned of “deep ...
4d
Pharmaceutical Technology on MSNSarepta refuses to pull gene therapy despite FDA requestSarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.
Most Americans encounter the Federal Trade Commission only if they’ve been scammed: It handles identity theft, fraud, and ...
Welcome to our live blog tracking the latest news and developments from the United States. Stay updated with real-time ...
This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...
Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...
GlobalData on MSN20h
Sarepta allowed to continue US Elevidys shipmentsIt has been a tumultuous two weeks for Sarepta; however, the FDA reauthorising US shipments of Elevidys will be a welcome development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results